Loading...

APC/Cyanine7 anti-human HLA-DR Antibody

Pricing & Availability
Clone
L243 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class II, MHC class II
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
L243_APCCyanine7_HLA-DR_Antibody_010719_updated.png
Human peripheral blood lymphocytes were stained with CD19 FITC and HLA-DR (clone L243) APC/Cyanine7 (left), or mouse IgG2a, κ APC/Cyanine7 isotype control (right)
  • L243_APCCyanine7_HLA-DR_Antibody_010719_updated.png
    Human peripheral blood lymphocytes were stained with CD19 FITC and HLA-DR (clone L243) APC/Cyanine7 (left), or mouse IgG2a, κ APC/Cyanine7 isotype control (right)
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
307617 25 tests 143 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
307618 100 tests 292 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Chimpanzee, Dog, Common Marmoset, Squirrel Monkey, Cotton-topped Tamarin
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The HLA-DR antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRa which depends on the correct folding of the aß heterodimer.19

Additional reported applications (for the relevant formats) include: immunoprecipitation8, Western blotting8, in vitro blocking of mixed lymphocyte reactions9,10, depeletion of MHC class II cells7, immunohistochemical staining of acetone-fixed frozen sections4,5, and spatial biology (IBEX)21,22. For sensitive functional assays, we recommend using the Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) (Cat. No. 307648, 307665 - 307669).

Additional Product Notes

BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)
  1. Brodsky F. 1984. Immunogenetics 19:179.
  2. Robbins P, et al. 1987. Human Immunol. 18:301.
  3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
  4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
  5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
  6. Zipf T, et al. 1981. Cancer Res. 41:4786.
  7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
  8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
  9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
  10. Wang RF, et al. 1999. Science 284:1351. (Block)
  11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
  12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
  13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
  15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
  17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
  18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
  19. Moro M, et al. 2005. BMC Immunol. 6:24.
  20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed
  21. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  22. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Takiguchi H, et al. 2021. Scientific Reports. 11(1):8282. PubMed
  2. Gorini G, et al. 2020. PLoS Pathog. 16:e1008377. PubMed
  3. Vaccari M, et al. 2018. Nat Med. 24:847. PubMed
  4. Sposito B, et al. 2021. Cell. 184:4953. PubMed
  5. Tripathi H, et al. 2020. J Mol Cell Cardiol. 149:95. PubMed
  6. Rha MS, et al. 2021. Immunity. 54:44. PubMed
  7. Ishizaka A, et al. 2016. J Virol. 90: 5665 - 5676. PubMed
  8. Krebs FK, et al. 2021. Cancer Med. . PubMed
  9. Schimek V, et al. 2022. Cell Death Dis. 13:113. PubMed
  10. Everts B, et al. 2010. PLoS One. 4:e667. PubMed
  11. Kubo M, et al. 2018. Oncol Rep. 39:417. PubMed
  12. Lundberg K, et al. 2016. PLoS One. 11: 0148838. PubMed
  13. Vogel S, et al. 2015. Sci Rep. 5: 18308. PubMed
  14. Woolsey C, et al. 2020. Scientific Reports. 10(1):3071.. PubMed
  15. Vetsika EK, et al. 2021. Cancers (Basel). 13:. PubMed
  16. Kristoff J, et al. 2019. EBioMedicine. 43:295. PubMed
  17. Woolsey C et al. 2019. Cell Rep. 28(12):3032-3046 . PubMed
  18. Demirel &, et al. 2007. J Biol Chem. 282:37836. PubMed
  19. Jankeel A, et al. 2020. J Virol. :94. PubMed
  20. Walk J, et al. 2019. Nat Commun. 10:874. PubMed
  21. Kuo HH, et al. 2018. Immunity. 48:1183. PubMed
  22. Lewis SA, et al. 2021. Front Immunol. 12:724015. PubMed
  23. Grivas A, et al. 2022. Front Immunol. 13:964274. PubMed
  24. Ohue Y, et al. 2014. Clin Cancer Res. 20:5052. PubMed
  25. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
  26. Arcangeli S, et al. 2022. J Clin Invest. 132: . PubMed
  27. Pesce E, et al. 2022. Front Immunol. 12:785941. PubMed
  28. Sureshchandra S, et al. 2021. iScience. 24:102690. PubMed
  29. Kurose K, et al. 2015. Clin Cancer Res. 21: 4327 - 4336. PubMed
  30. Swanson E, et al. 2021. eLife. 10:00. PubMed
  31. Hakimi AA, et al. 2019. Cancer Discov. 9:510. PubMed
  32. Sureshchandra S, et al. 2022. Cell Rep. 39:110938. PubMed
  33. Gopinath A, et al. 2022. NPJ Parkinsons Dis. 8:72. PubMed
  34. Lu J, et al. 2021. Front Immunol. 12:732612. PubMed
  35. Castro-Amarante M, et al. 2016. J Virol. 90: 2195 - 2207. PubMed
  36. Richardson JR, et al. 2018. Front Immunol. 2.182638889. PubMed
  37. Li YR, et al. 2021. Cell Rep Med. 2:100449. PubMed
  38. Mansouri S, et al. 2020. Mucosal Immunol. 0.954861111. PubMed
  39. Donini M, et al. 2011. Prostate. 72:566. PubMed
  40. Vaccari M, et al. 2019. Front Immunol. 10:1072. PubMed
  41. Reismann M, et al. 2014. J Surg Res. 187:197. PubMed
  42. NULL, et al. 2022. Cell. 185:916. PubMed
  43. Fu Y, et al. 2021. Cell Reports. 36(2):109344. PubMed
  44. Savage AK, et al. 2021. iScience. 24(5):102404. PubMed
  45. Pribyl M, et al. 2020. Mol Oncol. 2.252083333. PubMed
  46. Ball M, et al. 2016. PLoS One. 11: 0149600. PubMed
  47. D'Antoni ML, et al. 2019. Front Immunol. 2.353472222. PubMed
  48. Wosen JE, et al. 2019. Front Immunol. 1.784722222. PubMed
  49. Rhoades NS, et al. 2022. Cell Rep. 39:110725. PubMed
  50. Strand K, et al. 2022. Front Endocrinol (Lausanne). 13:856530. PubMed
  51. Grosche L, et al. 2020. Viruses. 12:. PubMed
  52. Finotti G, et al. 2016. J Leukoc Biol. 99: 107 - 119. PubMed
  53. Lonardi S, et al. 2020. Cancer Immunol Res. 829:8. PubMed
  54. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  55. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  56. Rodrigues E, et al. 2020. Nat Commun. 3.99375. PubMed
  57. Genge PC, et al. 2021. STAR Protoc. 2:100900. PubMed
  58. López-Peláez M, et al. 2022. Oncoimmunology. 11:2117321. PubMed
  59. Teirlinck A, et al. 2015. Infect Immun . 83: 3732-3739. PubMed
  60. Stich L, et al. 2022. Int J Mol Sci. 23:. PubMed
  61. Ferreira-Gomes M, et al. 2021. Nat Commun. 12:1961. PubMed
  62. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
RRID
AB_493587 (BioLegend Cat. No. 307617)
AB_493586 (BioLegend Cat. No. 307618)

Antigen Details

Structure
Ig superfamily, MHC class II, heterodimeric transmembrane protein, 36 kD heavy and 27 kD light chain
Distribution

B cells, activated T cells, monocytes/macrophages, dendritic cells, other APCs

Function
Peptide presentation
Ligand/Receptor
CD3/TCR, CD4
Cell Type
Antigen-presenting cells, B cells, Dendritic cells, Macrophages, Monocytes, T cells, Tregs
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
3. Edwards JA, et al. 1986. J. Immunol. 137:490.
4. van Es A, et al. 1984. Transplantation 37:65.
5. O'Doherty U, et al. 1994. Immunology 82:487.
6. Thomas R, et al. 1994. J. Immunol. 153:4016.
7. Grouard G, et al. 1996. Nature 384:364.

Gene ID
3122 View all products for this Gene ID 3123 View all products for this Gene ID
UniProt
View information about HLA-DR on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All HLA-DR Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human HLA-DR L243 FC
FITC anti-human HLA-DR L243 FC
PE anti-human HLA-DR L243 FC
PE/Cyanine5 anti-human HLA-DR L243 FC
Purified anti-human HLA-DR L243 FC,CyTOF®,IP,WB,Block,IHC-F
Biotin anti-human HLA-DR L243 FC
PE/Cyanine7 anti-human HLA-DR L243 FC
APC/Cyanine7 anti-human HLA-DR L243 FC
Alexa Fluor® 488 anti-human HLA-DR L243 FC,SB
Alexa Fluor® 647 anti-human HLA-DR L243 FC
Pacific Blue™ anti-human HLA-DR L243 FC
Alexa Fluor® 700 anti-human HLA-DR L243 FC
PerCP anti-human HLA-DR L243 FC
PerCP/Cyanine5.5 anti-human HLA-DR L243 FC
Brilliant Violet 605™ anti-human HLA-DR L243 FC
Brilliant Violet 421™ anti-human HLA-DR L243 FC
Brilliant Violet 570™ anti-human HLA-DR L243 FC
Brilliant Violet 711™ anti-human HLA-DR L243 FC
Brilliant Violet 785™ anti-human HLA-DR L243 FC
Brilliant Violet 510™ anti-human HLA-DR L243 FC
Ultra-LEAF™ Purified anti-human HLA-DR L243 FC,CyTOF®,IP,WB,Block,IHC-F
Brilliant Violet 650™ anti-human HLA-DR L243 FC
Purified anti-human HLA-DR (Maxpar® Ready) L243 FC,CyTOF®
PE/Dazzle™ 594 anti-human HLA-DR L243 FC
FITC anti-human HLA-DR L243 FC
APC/Fire™ 750 anti-human HLA-DR L243 FC
Pacific Blue™ anti-human HLA-DR L243 FC
APC anti-human HLA-DR L243 FC
PE/Dazzle™ 594 anti-human HLA-DR L243 FC
PE/Cyanine7 anti-human HLA-DR L243 FC
TotalSeq™-A0159 anti-human HLA-DR L243 PG
TotalSeq™-B0159 anti-human HLA-DR L243 PG
TotalSeq™-C0159 anti-human HLA-DR L243 PG
Brilliant Violet 750™ anti-human HLA-DR L243 FC
APC/Fire™ 750 anti-human HLA-DR L243 FC
PerCP/Cyanine5.5 anti-human HLA-DR L243 FC
APC/Fire™ 810 anti-human HLA-DR L243 FC
PE/Fire™ 640 anti-human HLA-DR L243 FC
PE anti-human HLA-DR L243 FC
Spark Violet™ 538 anti-human HLA-DR Antibody L243 FC
KIRAVIA Blue 520™ anti-human HLA-DR L243 FC
TotalSeq™-D0159 anti-human HLA-DR L243 PG
PE/Fire™ 810 anti-human HLA-DR L243 FC
GMP PE/Dazzle™ 594 anti-human HLA-DR L243 FC
Spark Violet™ 423 anti-human HLA-DR L243 FC
PerCP anti-human HLA-DR L243 FC
GMP FITC anti-human HLA-DR L243 FC
GMP APC anti-human HLA-DR L243 FC
GMP PE/Cyanine7 anti-human HLA-DR L243 FC
GMP Pacific Blue™ anti-human HLA-DR L243 FC
GMP APC/Fire™ 750 anti-human HLA-DR L243 FC
Spark Violet™ 500 anti-human HLA-DR L243 FC
GMP PerCP/Cyanine5.5 anti-human HLA-DR L243 FC
GMP PE anti-human HLA-DR L243 FC
Spark UV™ 387 anti-human HLA-DR L243 FC
Spark Blue™ 515 anti-human HLA-DR L243 FC
Spark NIR™ 685 anti-human HLA-DR L243 FC
Spark Blue™ 550 anti-human HLA-DR (Flexi-Fluor™) L243 FC
Spark Red™ 718 anti-human HLA-DR (Flexi-Fluor™) L243 FC
Go To Top Version: 3    Revision Date: 01.07.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account